| Aug 8 |
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
|
| Aug 8 |
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
|
| Jul 24 |
Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript
|
| Jul 23 |
Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones
|
| Jul 23 |
Crude Oil Down 2%; GE Aerospace Earnings Top Views
|
| Jul 23 |
Cellectar falls after updating pivotal data for lead asset
|
| Jul 23 |
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
|
| Jul 22 |
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
|
| Jun 27 |
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
|
| May 29 |
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
|
